Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted) (2017 - 2026)
Viking Therapeutics' (VKTX) quarterly EPS (Weighted Average and Diluted) came in at -$1.37 in Q1 2026, down 234.15% year-on-year from $1.02 in Q1 2025, and up 1.44% quarter-over-quarter from -$1.39 in Q4 2025.
Viking Therapeutics (VKTX) EPS (Weighted Average and Diluted) (2017 - 2026) Analysis & Trends
Viking Therapeutics has disclosed EPS (Weighted Average and Diluted) across 9 years of filings, most recently posting -$1.37 for Q1 2026.
- EPS (Weighted Average and Diluted) for Q1 2026 came in at -$1.37, down 234.15% year-over-year; the trailing twelve-month figure through Mar 2026 was -$4.15 (down 260.87% YoY), and the FY2025 annual result was -$3.19, down 215.84% from the prior year.
- EPS (Weighted Average and Diluted) came in at -$1.37 for Q1 2026 at Viking Therapeutics, up from -$1.39 in the prior quarter.
- In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.19 in Q2 2023 to a low of -$1.39 in Q4 2025.
- The 5-year median for EPS (Weighted Average and Diluted) is -$0.25 (2023), against an average of -$0.43.
- Across the five-year window, EPS (Weighted Average and Diluted) gained 17.39% in 2023 and plunged 334.37% in 2025, its largest moves.
- Viking Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.26 in 2022, then increased by 3.85% to -$0.25 in 2023, then retreated by 28.0% to -$0.32 in 2024, then slumped by 334.37% to -$1.39 in 2025, then increased by 1.44% to -$1.37 in 2026.
- The last three EPS (Weighted Average and Diluted) figures came in at -$1.37 (Q1 2026), -$1.39 (Q4 2025), and -$0.81 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 0.68 |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 3.06 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3,086.42 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 0.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 0.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 4.02 |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -0.61 |
| 10 | Viking Therapeutics | 3.50 Bn | 3.50 Bn | - | -1.37 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.37 |
| Dec 31, 2025 | -1.39 |
| Sep 30, 2025 | -0.81 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -0.41 |
| Dec 31, 2024 | -0.32 |
| Sep 30, 2024 | -0.22 |
| Jun 30, 2024 | -0.20 |
| Mar 31, 2024 | -0.26 |
| Dec 31, 2023 | -0.25 |
| Sep 30, 2023 | -0.23 |
| Jun 30, 2023 | -0.19 |
| Mar 31, 2023 | -0.25 |
| Dec 31, 2022 | -0.26 |
| Sep 30, 2022 | -0.21 |
| Jun 30, 2022 | -0.23 |
| Mar 31, 2022 | -0.21 |
| Dec 31, 2021 | -0.16 |
| Sep 30, 2021 | -0.17 |
| Jun 30, 2021 | -0.20 |